Breaking News

Aeterna Zentaris Names CCO

By Gil Roth | November 1, 2013

Dinges joins to guide commercial direction

Jude Dinges has been named senior vice president, chief commercial officer of Aeterna Zentaris Inc. as the company reorients itself to become a specialty biopharma company. AZ plans to commercialize its pipeline and pursue in-licensing and acquisition opportunities. The company is in the process of bringing macimorelin acetate to market as the first approved oral product for evaluating growth hormone deficiency in adults.

Mr. Dinges began his career nearly 30 years ago as a professional sales representative at Bristol Laboratories and later at Merck & Co., where he was promoted to positions with increased responsibilities in training, sales, management, marketing, and market development. While at Merck, he helped launch Cozaar, Fosamax, Singulair, Maxalt, Vioxx, and Vytorin. Mr. Dinges joined Novartis Pharmaceuticals in 2006 and became the Respiratory & Infectious Disease Specialty Medicines director in 2008. In 2009, he joined Amgen as executive director of Region Sales, Bone Health Business Unit, helping launch Prolia.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision